Page last updated: 2024-11-04

methixene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

methixene: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID4167
CHEMBL ID1201342
CHEBI ID51024
SCHEMBL ID149672
MeSH IDM0046452

Synonyms (77)

Synonym
MLS002153842 ,
smr001233205
BRD-A33711280-311-02-0
piperidine, 1-methyl-3-(thioxanthen-9-ylmethyl)-
piperidine, 1-methyl-3-(9h-thioxanthen-9-ylmethyl)-
BSPBIO_000381
metixeno [inn-spanish]
brn 0267181
tremoquil
methixen [german]
raunana
60 sj 1977
methyloxan
einecs 225-610-6
dalpan
metixene [inn:ban]
metixenum [inn-latin]
tremonil
metisene [dcit]
1-methyl-3-(thioxanthen-9-ylmethyl) piperidine
metisene
methixen
metixeno
metixenum
4969-02-2
CHEBI:51024 ,
tremaril
contalyl
methixene (*hydrochloride*)
metixene (*hydrochloride*)
1-methyl-3-(9h-thioxanthen-9-ylmethyl)piperidine
methixart
60 sj 1977 (*hydrochloride*)
9-(1'-methylpiperidine-3'-methyl)thioxanthene
tremonil (*hydrochloride*)
1-pipecoline, 3-(thioxanthen-9-yl)methyl-
1-methyl-3-(thioxanthen-9-ylmethyl)-1-piperidine
nsc78194
atosil
1-methyl-3-(9h-thioxanthen-9-yl-methyl)piperidine
trest
methixene
DB00340
metixene
PRESTWICK2_000491
BPBIO1_000421
PRESTWICK3_000491
PRESTWICK0_000491
PRESTWICK1_000491
SPBIO_002302
NCIOPEN2_008789
L001125
metixene (inn)
D08209
FT-0653054
FT-0651957
CHEMBL1201342 ,
A827806
32vy6l26zw ,
unii-32vy6l26zw
4-27-00-01421 (beilstein handbook reference)
AKOS015895048
gtpl7232
metixene [inn]
methixene [mi]
metixene [who-dd]
SCHEMBL149672
cid_71177
bdbm79211
DTXSID1047867
metixen
MJFJKKXQDNNUJF-UHFFFAOYSA-N
Q1176336
CS-0069454
HY-120081
1-methyl-3-[(9h-thioxanthen-9-yl)methyl]piperidine
EN300-25300514
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
antiparkinson drugA drug used in the treatment of Parkinson's disease.
muscarinic antagonistA drug that binds to but does not activate muscarinic cholinergic receptors, thereby blocking the actions of endogenous acetylcholine or exogenous agonists.
histamine antagonistHistamine antagonists are the drugs that bind to but do not activate histamine receptors, thereby blocking the actions of histamine or histamine agonists.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
thioxanthenesThioxanthene and its substitution derivatives.
piperidines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)IC50 (µMol)1.60000.00052.773925.1700AID600984
Muscarinic acetylcholine receptor M3Rattus norvegicus (Norway rat)IC50 (µMol)1.60000.00052.891925.1700AID600984
Muscarinic acetylcholine receptor M4Rattus norvegicus (Norway rat)IC50 (µMol)1.60000.00052.747825.1700AID600984
Muscarinic acetylcholine receptor M5Rattus norvegicus (Norway rat)IC50 (µMol)1.60000.00052.780225.1700AID600984
Muscarinic acetylcholine receptor M2Rattus norvegicus (Norway rat)IC50 (µMol)1.60000.00053.314249.5000AID600984
CholinesteraseEquus caballus (horse)IC50 (µMol)1.60000.00002.22149.4000AID600984
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Proteasome subunit alpha type-6Homo sapiens (human)EC50 (µMol)11.90007.80008.85009.9000AID1794859
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (4)

Processvia Protein(s)Taxonomy
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit alpha type-6Homo sapiens (human)
regulation of inflammatory responseProteasome subunit alpha type-6Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityProteasome subunit alpha type-6Homo sapiens (human)
proteolysis involved in protein catabolic processProteasome subunit alpha type-6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
RNA bindingProteasome subunit alpha type-6Homo sapiens (human)
endopeptidase activityProteasome subunit alpha type-6Homo sapiens (human)
protein bindingProteasome subunit alpha type-6Homo sapiens (human)
purine ribonucleoside triphosphate bindingProteasome subunit alpha type-6Homo sapiens (human)
NF-kappaB bindingProteasome subunit alpha type-6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (13)

Processvia Protein(s)Taxonomy
nucleusProteasome subunit alpha type-6Homo sapiens (human)
cytoplasmProteasome subunit alpha type-6Homo sapiens (human)
proteasome complexProteasome subunit alpha type-6Homo sapiens (human)
P-bodyProteasome subunit alpha type-6Homo sapiens (human)
nucleusProteasome subunit alpha type-6Homo sapiens (human)
nucleoplasmProteasome subunit alpha type-6Homo sapiens (human)
cytosolProteasome subunit alpha type-6Homo sapiens (human)
ribosomeProteasome subunit alpha type-6Homo sapiens (human)
nuclear matrixProteasome subunit alpha type-6Homo sapiens (human)
myofibrilProteasome subunit alpha type-6Homo sapiens (human)
sarcomereProteasome subunit alpha type-6Homo sapiens (human)
extracellular exosomeProteasome subunit alpha type-6Homo sapiens (human)
proteasome core complexProteasome subunit alpha type-6Homo sapiens (human)
proteasome core complex, alpha-subunit complexProteasome subunit alpha type-6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID600984Inhibition of Equine serum BChE using butyrylthiocholine iodide as a substrate after 20 mins by Ellman's assay2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Quinolizidinyl derivatives of bi- and tricyclic systems as potent inhibitors of acetyl- and butyrylcholinesterase with potential in Alzheimer's disease.
AID600983Inhibition of bovine erythrocyte AChE using acetylthiocholine iodide as a substrate at 10 uM after 20 mins by Ellman's assay2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Quinolizidinyl derivatives of bi- and tricyclic systems as potent inhibitors of acetyl- and butyrylcholinesterase with potential in Alzheimer's disease.
AID1794859Proteasome Activity Assay from Article 10.1021/acschembio.7b00489: \\Small Molecule Enhancement of 20S Proteasome Activity Targets Intrinsically Disordered Proteins.\\2017ACS chemical biology, 09-15, Volume: 12, Issue:9
Small Molecule Enhancement of 20S Proteasome Activity Targets Intrinsically Disordered Proteins.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (61.54)18.7374
1990's1 (7.69)18.2507
2000's0 (0.00)29.6817
2010's4 (30.77)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.98

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.98 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index4.13 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.98)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (7.14%)5.53%
Reviews0 (0.00%)6.00%
Case Studies2 (14.29%)4.05%
Observational0 (0.00%)0.25%
Other11 (78.57%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]